Amendments to the Claims:

26. (Currently amended) A monovalent influenza vaccine composition comprising an influenza virus component that ~~which~~ is a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 μg of haemagglutinin per dose ~~or no more than 15 μg per combined dose of vaccine~~, and wherein the adjuvant is ~~an~~ at least one aluminium salt ~~or salts~~.

27. (Currently amended) ~~A~~ The vaccine composition according to claim 26, wherein the influenza virus antigen is in the form of purified whole influenza virus.

28. (Cancelled).

29. (Currently amended) ~~A~~ The vaccine composition according to claim 26, wherein the adjuvant is a mixture of aluminium hydroxide and aluminium phosphate.

30. (Currently amended) ~~A~~ The vaccine composition according to claim 29, wherein the amount of aluminium phosphate exceeds the amount of aluminium hydroxide.

31. (Currently amended) ~~A~~ The vaccine composition according to claim 26, wherein the aluminium salts are present in the range 0.4 to 1.0 mg per vaccine dose.

32. (Currently amended) ~~A~~ The vaccine composition according to claim 26, wherein ~~in which~~ the low antigen dose is less than 10 μg of haemagglutinin per dose ~~or per combined dose of vaccine~~.

33. (Currently amended) ~~A~~ The vaccine composition according to claim 32, wherein ~~in which~~ the antigen dose is between 0.1 μg and 7.5 μg or between 1 and 5 μg of haemagglutinin per dose ~~or per combined dose of vaccine~~.

34. (Currently amended) ~~A~~ The vaccine composition according to claim 26, wherein the influenza virus antigen is substantially free of host cell contamination.

35. (Currently amended) ~~A~~ The vaccine composition according to claim 26, wherein the influenza virus component is purified by a method ~~which~~ that includes a protease incubation step to digest non-influenza virus proteins.

36-40. (Canceled).

41. (Currently amended) A method for the production of an influenza vaccine for a pandemic situation, said ~~which~~ method ~~comprises~~ comprising admixing egg-derived influenza virus antigen from a single influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, with a suitable adjuvant, wherein the adjuvant is ~~an~~ at least one aluminium salt ~~or salts~~, and providing vaccines lots ~~or vaccine kits which~~ that contain less than 10 μg influenza haemagglutinin antigen per dose ~~or no more than 15 μg haemagglutinin per combined dose.~~

42. (Currently amended) ~~A~~ The method according to claim 41, wherein the antigen is highly purified.

43. (Currently amended) ~~A~~ The method according to claim 41, wherein the influenza virus antigen is in the form of whole influenza virus particles.

44. (Currently amended) The vaccine composition of claim 26, wherein the antigen is selected from an H2 antigen ~~such as H2N2~~ and an H5 antigen ~~such as H5N1~~.

45. (Canceled).

46. (Currently amended) The method of claim 41, wherein the antigen is selected from an H2 antigen ~~such as H2N2~~ and an H5 antigen ~~such as H5N1~~.

47-50. (Canceled).

51. (New) A method for treating a patient with a monovalent influenza vaccine composition, said method comprising the step of administering to the patient an influenza virus component that is a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated

with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 μg of haemagglutinin per dose or no more than 15 μg per administered dose of vaccine, and wherein the adjuvant is at least one aluminium salt.

52. (New) The method according to claim 51, wherein there is more than one separate administered dose, the total of which is less than 15 μg of haemagglutinin or no more than 15 μg of vaccine.

53. (New) The vaccine composition according to claim 26, wherein the adjuvant is chosen from the group of: aluminium hydroxide and aluminium phosphate.

54. (New) The vaccine composition according to claim 44, wherein the H2 antigen is H2N2, and the H5 antigen is H5N1.

55. (New) The method according to claim 46, wherein the H2 antigen is H2N2, and the H5 antigen is H5N1.

56. (New) A kit comprising a monovalent influenza vaccine composition, wherein said composition comprises an influenza virus component that is a low dose of less than 15 μg of haemagglutinin per dose, of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein said kit contains less than 10 μg influenza haemagglutinin antigen per administered dose.